Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss
- Conditions
- Agitation with Dementia of the Alzheimer's TypeMedDRA version: 20.0Level: PTClassification code: 10012271Term: Dementia Alzheimer's type Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2024-513835-25-00
- Lead Sponsor
- Suven Life Sciences Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 375
1. Participant and/or the participant’s LAR/caregiver can understand the written informed consent, provide signed and witnessed written informed consent, and agree to comply with protocol requirements prior to beginning any study procedures. 2. Is =50 years of age at Visit 1 and has a diagnosis of dementia of the Alzheimer’s type according to the NIA-AA 2011 criteria. Biomarkers will not be considered for eligibility. 3. Has onset of agitation symptoms at least 2 weeks prior to Visit 1. 4. Has confirmed agitation using the IPA Consensus Provisional Definition of Agitation in Cognitive Disorders. 5. Has an MRI or CT scan performed after onset of Alzheimer's disease symptoms and prior to randomization with findings consistent with the diagnosis of dementia of the Protocol CTP3S1502HT6, Page 49 and without any other clinically significant comorbid pathologies. 6. Has a score between 5 and 26 (both inclusive) on MMSE at Visit 1. 7. Has a clinically significant agitation/aggression (score of =4) as measured by the NPI-12 A/A at Visits 1 and 2. 8. Must be receiving treatment with stable doses of either a cholinesterase inhibitor or memantine or both for =3 months prior to Visit 1 and likely to be maintained on his/her current dose for the duration of the study. 9. Has no change to medications targeting behavioral manifestations of AD within 4 weeks prior to Visit 2. Lorazepam can be administered in a dose =1.5 mg/day and not to exceed 3 days in a 7-day period. Concomitant use of lorazepam must be recorded during visits. 10. Is permitted to use low-dose trazodone (up to 100 mg/day), eszopiclone, zolpidem, zopiclone, or zaleplon for nighttime management of insomnia. Insomnia medications must not be administered within 8 hours prior to the efficacy and/or safety assessments. 11. Is permitted to use anxiolytic medications (including benzodiazepine), and antidepressants (with the exclusion of tricyclic antidepressants), provided they have been on a stable dose for =4 weeks prior to Visit 1., 12. Is permitted to use supplements, medical foods, or pharmaceuticals specifically for the treatment of dementia, agitation, or sleep, containing omega-3 fatty acids, melatonin, vitamin B12, folate, or valerian root. However, the dose should be stable for =4 weeks prior to Visit 1 and must remain stable throughout the study. All stable supplements require review and approval by the medical monitor prior to randomization. 13. Has a person (ie, caregiver) who is qualified, willing, and able to provide accurate information regarding the participant's cognitive and functional abilities and will accompany the participant to study visits. The caregiver should have face-to-face contact with the participant for a minimum of approximately 8 hours per week spread over 3 to 5 days during the week. 14. Participants who are independent living, having in-home services, or living in assisted living or nursing homes. The participant can participate in this study if his/her caregiver ensures the administration of the study drug. 15. Has vision and hearing (corrected) sufficient to comply with the testing procedures. Both participant and caregiver must be able to read and understand the written information and have literacy skills to ensure compliance with the visit procedures. 16. Has no clinically significant abnormalities in general health, physical examination, neurological examination, ECG recording, or laboratory assessments. For ALT, AST, or TBL, clinically s
1.Female participants who are pregnant or breast feeding. 2.Sexually active females of childbearing potential and male participants are not practicing two different methods of birth control with their partner. 3.Has history of confirmed COVID-19 within 3 months prior to Visit 1. 4.Has a diagnosis of dementia due to other non-Alzheimer disorders. 5.Has a history of stroke, documented TIAs, and/or pulmonary embolism within the last 12 months. 6.Has a diagnosis of schizophrenia, bipolar disorder, or current untreated/uncontrolled MDD or participants whose C-SDD scores are suggestive of probable depression (ie, scores =12) at Visits 1 or 2. 7.Has symptoms of agitation that are not secondary to AD. 8.Has symptoms of delirium or history of delirium within 1 month prior to Visit 1. 9.Has used or will continue to use MAOIs, linezolid, tricyclic antidepressants, or intravenous methylene blue within 14 days prior to Visit 1. 10.Has uncontrolled cardiac disease or hypertension. 11.All antipsychotics are prohibited and should be discontinued as appropriate. 12.Centrally acting anticholinergic medications are prohibited. 13.CYP3A4 substrates with narrow therapeutic index are prohibited and should be discontinued as appropriate. 14.Use of any medications/supplements/foods with known inhibitoryinducer effects on CYP3A4 should be discontinued from screening through EOT visit. 15.Use of herbal and dietary supplements that cause liver injury. Participants on stable use for at least 4 months prior to Visit 1 are allowed; however, herbal and dietary supplement dose changes and new herbal and dietary supplements are not allowed during the study., 16.Has a history or current evidence of QT prolongation syndrome, or Torsade de Pointes, as determined by ECG at Visits 1 or 2. 17.Has bradycardia (100 bpm) on the ECG at Visits 1 or 2. 18.Has uncontrolled type-1 or type-2 diabetes (defined as HbA1c >6.5% at Visit 1). 19.Has cancer, a malignant tumor, or has been treated for an active malignancy within the past 5 years. Participants with stable untreated prostate or cervical cancer, localized squamous cell cancer, or basal cell cancer are permitted. 20.Has clinically significant hepatic impairment. 21.Is treated or likely to require treatment during the study with any medications prohibited by the study protocol. 22.Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator at Visits 1 or 2. 23.History of significant head injury, seizures, or any other unexplained, recurrent loss of consciousness for more than 15 minutes within 12 months of Visit 1. 24.Poorly controlled psychosis and other psychiatric disorder that, in the opinion of the investigator, would interfere with the participant’s ability to be compliant with the study protocol. 25.Known history of substance use disorder within 1 year prior to first dose of study drug, not including caffeine and nicotine. 26.Current implantable intracranial stimulator or history of intracranial ablation surgery. 27.Repetitive transcranial magnetic stimulation within 3 months prior to Visit 1. 28.Participation in experimental interventional treatments, including immunotherapy, for any aspects of AD in the past 6 months or 5 half-lives of the experimental drug product (whichever is longer), prior to the first dose of study drug. If the participant was on placebo arm of disease-modifying treatments, participation in t
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To evaluate the efficacy of masupirdine (50 mg and 100 mg compared to placebo for agitation as measured by the CMAI items score aligning to the IPA agitation criteria domains (physical aggression, excessive motor activity, and verbal aggression) after 12 weeks of treatment.;Secondary Objective: To measure whether the effects of masupirdine (50 mg and 100 mg) are substantial enough to be detected by a skilled and experienced clinician based on a direct examination of the participant and an interview of the participant's caregiver., To assess the safety of masupirdine;Primary end point(s): Change in CMAI items score aligning to the IPA agitation criteria domains from baseline to Week 12
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Improvement in mADCS-CGI-C at Week 12;Secondary end point(s):Change in CGI-S score as related to agitation from baseline to Week 12;Secondary end point(s):Change in CaGI-S score as related to agitation from baseline to Week 12;Secondary end point(s):Improvement in CaGI-C at Week 12;Secondary end point(s):Change in behavioral and psychological symptoms as measured by NPI-12 from baseline to Week 12;Secondary end point(s):Change in memory and cognitive behaviors as studied using MMSE total score from baseline to Week 12;Secondary end point(s):Change in CMAI items score aligning to the IPA agitation criteria domains from baseline to Weeks 2, 4, and 8;Secondary end point(s):Change in C-SDD from baseline to Week 12